Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial (Q45073151)
Jump to navigation
Jump to search
scientific article published on 13 November 2017
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial |
scientific article published on 13 November 2017 |
|
Statements
1 reference
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial (English)
1 reference
Suzette Delaloge
1 reference
Bent Ejlertsen
1 reference
Hiroji Iwata
1 reference
Beverly Moy
1 reference
Miguel Martin
1 reference
Frankie A Holmes
1 reference
Gunter von Minckwitz
1 reference
Stephen K L Chia
1 reference
Janine Mansi
1 reference
Carlos H Barrios
1 reference
Michael Gnant
1 reference
Zorica Tomašević
1 reference
Neelima Denduluri
1 reference
Erhan Gokmen
1 reference
Anna Bashford
1 reference
Manuel Ruiz Borrego
1 reference
Sung-Bae Kim
1 reference
Erik Hugger Jakobsen
1 reference
Audrone Ciceniene
1 reference
Friedrich Overkamp
1 reference
Joan B Heijns
1 reference
Anne C Armstrong
1 reference
John S Link
1 reference
Anil Abraham Joy
1 reference
Richard Bryce
1 reference
Alvin Wong
1 reference
Susan Moran
1 reference
Bin Yao
1 reference
Feng Xu
1 reference
Alan Auerbach
1 reference
Marc Buyse
1 reference
Arlene Chan
1 reference
ExteNET Study Group
1 reference
13 November 2017
1 reference
1 reference
Identifiers
1 reference